The ALK Inhibitor PF-06463922 Is Effective as a Single Agent in Neuroblastoma Driven by Expression of ALK and MYCN

DMM Disease Models and Mechanisms - United Kingdom
doi 10.1242/dmm.024448
Full Text
Abstract

Available in full text

Date
Authors
Publisher

The Company of Biologists

Related search

The Targetable Kinase PIM1 Drives ALK Inhibitor Resistance in High-Risk Neuroblastoma Independent of MYCN Status

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2019English

Aberrant Activation of ALK Kinase by a Novel Truncated Form ALK Protein in Neuroblastoma

Oncogene
Cancer ResearchGeneticsMolecular Biology
2012English

NeuroD1 Promotes Neuroblastoma Cell Growth by Inducing the Expression of ALK

Cancer Science
Cancer ResearchMedicineOncology
2015English

Repotrectinib (TPX-0005), Effectively Reduces Growth of ALK Driven Neuroblastoma Cells

Scientific Reports
Multidisciplinary
2019English

ALK in Neuroblastoma: Biological and Therapeutic Implications

Cancers
Cancer ResearchOncology
2018English

Aurora B Kinase Is a Potent and Selective Target in MYCN-driven Neuroblastoma

Oncotarget
Oncology
2015English

Glutathione Biosynthesis Is Upregulated at the Initiation of MYCN-driven Neuroblastoma Tumorigenesis

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2016English

Sweyjawbu Expression Is a Predictor of ALK Rearrangement Status in Lymphoma

Oncotarget
Oncology
2016English

ALK Is a Critical Regulator of the MYC-signaling Axis in ALK Positive Lung Cancer

Oncotarget
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy